Holen Sie sich die Stockscreener-App
4.17
8.31%
0.32
Schlusskurs vom Vortag:
$3.85
Offen:
$3.91
24-Stunden-Volumen:
33.38M
Relative Volume:
0.81
Marktkapitalisierung:
$2.15B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-2.6903
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
+0.72%
1M Leistung:
-31.75%
6M Leistung:
+1.83%
1J Leistung:
-27.48%
1-Tages-Spanne:
$3.85
$4.26
1-Wochen-Bereich:
$3.81
$4.37
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.17 | 2.01B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
Recursion (RXRX) Jumps 8% on Bargain-Hunting - Finviz
Recursion Pharmaceuticals Surpasses Third-Quarter Expectations, Announces Milestone with Roche - StocksToTrade
Recursion Pharmaceuticals Surges Amid CEO Transition and Strong Q3 Results - StocksToTrade
Soaring Stock: Recursion Pharmaceuticals’ Latest Surge - timothysykes.com
Recursion seeks to deliver results, and a VC sees a wave of M&A coming - statnews.com
Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? - Finviz
Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results - statnews.com
Recursion’s Khan Era: Proving AI Can Crack Drug Discovery - WebProNews
RXRX’s Anemic Revenue Misses Estimates - timothysykes.com
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
How Recursion Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & Capital Efficiency Focused Strategies - newser.com
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
CFO Taylor Surrenders 11,908 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
Is Recursion Pharmaceuticals a Meme Stock? - MSN
How Recursion Pharmaceuticals Inc. stock reacts to bond yields2025 Biggest Moves & Trade Opportunity Analysis Reports - newser.com
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
Is Recursion Pharmaceuticals Inc. stock poised for growth2025 Analyst Calls & Fast Entry High Yield Stock Tips - newser.com
Recursion Pharmaceuticals (RXRX) Is Down 11.7% After Revenue Miss and CEO Transition – Has the Bull Case Changed? - simplywall.st
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.Analyst Downgrade & High Yield Stock Recommendations - newser.com
Recursion Pharmaceuticals, Inc.Class A Common Stock (NQ: RXRX - FinancialContent
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? (RXRX) - Seeking Alpha
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - MSN
Has Recursion Pharmaceuticals Inc. formed a bullish divergenceOil Prices & Free Technical Confirmation Trade Alerts - newser.com
How Recursion Pharmaceuticals Inc. stock valuations compare to rivalsDay Trade & Community Consensus Trade Alerts - newser.com
Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5 From $4.80, Keeps Equalweight Rating - MarketScreener
Recursion Pharmaceuticals Inc. stock volume spike explainedTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Using Bollinger Bands to evaluate Recursion Pharmaceuticals Inc.Weekly Volume Report & Fast Gain Swing Alerts - newser.com
Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference - MSN
Penny Stocks To Watch NowNovember 14th - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral
Published on: 2025-11-16 05:12:39 - newser.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative
RXRX Faces Setback as Revenue Misses Estimates - StocksToTrade
Recursion Pharmaceuticals’ Revenue Miss Drives Stock Downward - StocksToTrade
Published on: 2025-11-14 18:05:32 - newser.com
Recursion Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:RXRX) 2025-11-14 - Seeking Alpha
Recursion Pharmaceuticals’ Financial Struggles: What’s Next? - timothysykes.com
Recursion Pharmaceuticals Reports Q3 Revenue Fall Short of Expectations - timothysykes.com
Recursion Pharmaceuticals Stock Plummets Amid Q3 Revenue Miss - timothysykes.com
Is it time to cut losses on Recursion Pharmaceuticals Inc.Inflation Watch & Verified Short-Term Trading Plans - newser.com
Change at the top of Recursion as co-founder leaves CEO role - pharmaphorum
Recursion Pharmaceuticals (RXRX): Assessing Valuation Following CEO Appointment and Disappointing Earnings Results - simplywall.st
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):